CS604: Extrusion-Stable Fermentation Bioactive Complex for Canine Immune Modulation & Gut Health

1. EXECUTIVE OVERVIEW CS604 is a proprietary, heat-inactivated fermentation bioactive complex engineered for integration into commercial pet foods, treats, and veterinary prescription diets. Quantified and standardized via its reference marker CS301, CS604 acts as a selective upstream immune modulator specifically targeted at managing canine inflammatory skin conditions (such as atopic dermatitis) and maintaining gut mucosal integrity without inducing systemic immunosuppression.

Unlike live probiotics, fragile enzymes, or heat-sensitive botanical extracts, CS604 delivers total thermal stability, retaining 100% of its biological activity after exposure to high-temperature kibble extrusion and drying processes. As a 100% inactivated matrix with zero live organisms, CS604 completely eliminates concerns regarding biological strain spillover, live microbial contamination, or complex regulatory hurdles, providing a seamless "Plug-and-Play" bioactive solution for global pet nutrition manufacturers.

2. KEY SCIENTIFIC & COMMERCIAL ADVANTAGES

• Superior Thermal Stability (Extrusion-Ready): Extrusion cooking in commercial pet food manufacturing exposes ingredients to extreme thermal stress. CS604 is natively heat-stable, demonstrating full retention of anti-inflammatory efficacy post-extrusion.
• Upstream Selective Cytokine Regulation: CS604 selectively downregulates primary pro-inflammatory cytokines, achieving ~60% reduction in TNF-α and ~50% reduction in IL-6 in validated models. Crucially, it operates via selective modulation rather than broad immunosuppression, leaving essential basal mucosal immunity (IgA, IL-2) intact.
• Standardization & Reproducibility: Batch-to-batch consistency is guaranteed through quantification of standardized reference chemical marker CS301, ensuring rigid analytical specification required for global compliance.
• Zero Biological & IP Risk: Because CS604 comprises a heat-killed matrix, there is no risk of proprietary production strain leakage, environmental contamination, or living organism transfer.

3. MECHANISM & PROOF-OF-CONCEPT In vivo preclinical evaluations demonstrate that CS604 targets the gut-skin axis by modulating inflammatory cascades:

• Skin Health: Downregulates circulating TNF-α and IL-6 levels, reducing cutaneous erythema and pruritus associated with canine dermatitis.
• Gut Barrier Integrity: Maintains intestinal tight junction architecture and promotes balanced mucosal IgA production against environmental allergens.

4. TARGET PRODUCT APPLICATIONS

• Commercial Dry Kibble: Directly added to base pre-mix prior to high-temp extrusion.
• Prescription Veterinary Diets: Target therapeutic formulas for canine dermatology and gastroenterology.
• Functional Treats & Chews: Easily incorporated into cold-form or baked functional treats.

5. PROPOSED PARTNERSHIP MODEL We are seeking global strategic partners (pet food enterprises or veterinary pharma) under an Asset-Light framework:

• Out-Licensing Strategy: Out-licensing agreements structured on Net Sales royalties while retaining 100% underlying IP and strain trade secrets.
• Manufacturing & Production Rights: Partners acquire manufacturing/formulation rights to produce or contract-manufacture the CS604 active matrix utilizing our proprietary fermentation know-how.
• Partner-Funded Validation: All species-specific clinical trials, target product formulations, and regulatory registrations are fully sponsored and managed by the global partner.